Company profile: Eurocine Vaccines
1.1 - Company Overview
Company description
- Provider of nasal flu vaccines for children and the elderly, managing preclinical and clinical development, scalability into manufacturing, business development, and funding. Offers Endocine, a nasal vaccine adjuvant used in clinical trials showing safety and tolerability in over 400 human subjects; an HSV-2 therapeutic vaccine candidate; and vaccine development services from conceptualization to commercialization.
Products and services
- Endocine: A clinical-stage nasal vaccine adjuvant used in human clinical trials, showing safety and tolerability in over 400 subjects, supporting nasal vaccine development programs
- Vaccine development services: Scale-up-ready programs shepherding candidates from conceptualization to commercialization, including preclinical and clinical development, scalability into manufacturing, plus business development and funding
- HSV-2 vaccine candidate: An investigational therapeutic vaccine targeting Herpes simplex virus type 2, currently under development
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Eurocine Vaccines
Earth Science Tech
HQ: United States
Website
- Description: Provider of science-based biotechnology offerings bringing Nature's Pharmacy to the public, operating RxCompoundStore, a Miami compounding pharmacy licensed in 23 states; Peaks Curative, a telemedicine platform for men's and women's health offering ED products via a proprietary tadalafil gummy; Avenvi, a Miami real estate development firm; and Mister Meds, a Texas wellness-focused pharmacy.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Earth Science Tech company profile →
Selux Diagnostics
HQ: United States
Website
- Description: Provider of next-generation phenotyping solutions for rapid antimicrobial susceptibility testing (AST). Offers the Selux NGP System, proprietary 384-well panels delivering exact MICs across a wide range of antibiotics, the Selux Separator and Inoculator for automated sample preparation from positive blood cultures, and Selux Site Software to streamline workflow and deliver actionable AST results.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Selux Diagnostics company profile →
Cerexa
HQ: United States
Website
- Description: Provider of novel anti-infective therapies for serious and life-threatening infections; develops a portfolio of treatments including Ceftaroline Acetate/Ceftaroline, an injectable cephalosporin used for bacterial infections.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cerexa company profile →
Qpex Biopharma
HQ: United States
Website
- Description: Provider of antibiotic agents addressing critical needs in infectious disease treatment and antimicrobial resistance for inpatient and outpatient care. Portfolio includes QPX7728, an ultra-broad-spectrum beta-lactamase inhibitor; OMNIvance (Xeruborbactam + Meropenem) for gram-negative infections; ORAvance, an oral Xeruborbactam prodrug enhancing oral beta-lactams; and QPX9003, a lipopeptide for MDR gram-negative pathogens.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Qpex Biopharma company profile →
Iomai
HQ: United States
Website
- Description: Provider of vaccines and immune system stimulants delivered via transcutaneous immunization (TCI), a novel needle-free technology that taps antigen-presenting cells in the outer layers of the skin to generate an enhanced immune response.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Iomai company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Eurocine Vaccines
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Eurocine Vaccines
2.2 - Growth funds investing in similar companies to Eurocine Vaccines
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Eurocine Vaccines
4.2 - Public trading comparable groups for Eurocine Vaccines
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →